Talphera, Inc. - Common Stock TLPH 深 滬
等待開盤 09-10 09:30:00 美东时间
0.853
+0.034
+4.15%
華盛通- 最 高0.96
- 今 開0.77
- 成交量 272.76万股
- 最 低 0.7418
- 昨 收 0.819
- 總市值 1750.59万
- 52周最高 1.19
- 市盈率 靜 --
- 換手率 13.29%
- 52周最低 0.38
- 委 比 -90.78%
- 總股本 2052.27万
- 歷史最高 272.80
- 量 比 0.19
- 振 幅 26.64%
- 歷史最低 0.38
- 每 手 1
- 風險率 0.20%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Talphera shares are trading higher after CorMedix made a $5M minority investment, purchasing 9,090,909 shares at $0.55 each.
Talphera shares are trading higher after CorMedix made a $5M minority investmen...
09-08 20:33
Earnings Scheduled For August 14, 2025
Companies Reporting Before The Bell • Sunlands Technology (NYSE:STG) is likely ...
08-14 16:32
A Preview Of Talphera's Earnings
Talphera (NASDAQ:TLPH) is preparing to release its quarterly earnings on Thursd...
08-14 01:02
Talphera Granted Extension for Nasdaq Compliance
Talphera ( ($TLPH) ) has shared an update. On June 5, 2025, Talphera, Inc. rece...
06-06 05:31
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Theriva Biologics (AMEX:TOVX) stock moved upwards by 47.4% to $0.72 du...
06-03 05:05
Talphera Q1 EPS $(0.10) Beats $(0.14) Estimate, Sales $27.00K
Talphera (NASDAQ:TLPH) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 37.5 percent increase over losses of $(0.16) per share from the same
05-15 04:12
Earnings Scheduled For May 14, 2025
Companies Reporting Before The Bell • Cellebrite DI (NASDAQ:CLBT) is expected t...
05-14 16:32
美股大行评级 | 潜在涨幅4159%！HC Wainwright & Co.上调BiomX目标价至21美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1114111385008877568.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持BiomX(PHGE)"买入"评级，目标价从2美元升至21美元</p> <p>• HC Wainwright & Co.：维持Unicycive Therapeu
04-02 09:42
Talphera Expects Registrational NEPHRO CRRT Study To Be Completed By The End Of 2025
Cash and investments at December 31, 2024 of $8.9 million, together with the private placement financing recently announced of up to $14.8 million, expected to provide capital through target completion of the NEPHRO
04-01 05:49
AcelRx Pharmaceuticals GAAP EPS of -$0.07 beats by $0.09
AcelRx Pharmaceuticals press release (NASDAQ:TLPH): Q4 GAAP EPS of -$0.07 beats by $0.09. Shares +0.06%. The cash and cash equivalents balance was $8.9 million as of December 31, 2024. 2025 Expense Gu...
04-01 04:07
